-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Benzinga·08/06/2026 14:00:48
Listen to the news
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.